In Silico tool for predicting, designing and scanning IL-2 inducing peptides
Interleukin-2 (IL-2) based immunotherapy has been approved for treating certain types of cancer, as IL-2 plays a crucial role in regulating the immune system. In this study, we developed a method for predicting IL-2-inducing peptides. Our method was trained, tested, and validated on a main dataset containing 6,574 experimentally validated Major histocompatibility complex (MHC) binders, including 3,429 IL-2-inducing and 3,145 non-inducing peptides. A primary analysis of IL-2 inducing and non-inducing peptides revealed that certain residues, such as alanine and leucine, are more abundant in IL-2-inducing peptides. Initially, we developed alignment-based methods, which demonstrated high precision but limited coverage. Subsequently, we developed artificial intelligence-based models, including machine learning (ML), deep learning (DL), and large language models (LLM), to predict IL-2-inducing peptides. Our Extra Tree-based model, developed using dipeptide composition and peptide length, achieved a maximum AUC of 0.82. Finally, we constructed ensemble models that combined artificial intelligence and alignment-based methods. Our best ensemble model, which integrates the Extra Tree-based model with MERCI, achieved the highest AUC of 0.84 and an MCC of 0.51 on the main dataset. One limitation of the main dataset is that both IL-2-inducing and non-inducing peptides are MHC binders. To address this limitation, we created two additional datasets: Alternate Dataset 1, consisting of 3,429 IL-2-inducing peptides and 3,429 non-inducing peptides (MHC non-binders), and Alternate Dataset 2, consisting of 3,429 IL-2-inducing peptides and 3,439 non-inducing peptides (MHC binders + MHC non-binders). Our best ensemble model achieved AUCs of 0.9 and 0.8 with MCCs of 0.61 and 0.44 on Alternate Datasets 1 and 2, respectively. To assist the scientific community, we have integrated the best models from this study into a standalone software and web server, IL2pred, which enables users to predict, scan, and design IL-2-inducing peptides ( https://webs.iiitd.edu.in/raghava/il2pred/ ).
Authors
- Dilraj Kaur (ORCID: https://orcid.org/0000-0002-2589-3613)
- Gajendra P. S. Raghava (ORCID: https://orcid.org/0000-0002-8902-2876)
- Anjali Lathwal (ORCID: https://orcid.org/0000-0001-9810-8893)
- Rajesh Kumar (ORCID: https://orcid.org/0000-0002-9835-3650)
- Naman Kumar Mehta (ORCID: https://orcid.org/0009-0009-0244-2826)
Institutions
- Indraprastha Institute of Information Technology Delhi (IN)
- Institute of Cancer Research (GB)
- Cancer Research UK (GB)
- National Cancer Institute (US)
- Indira Gandhi Delhi Technical University for Women (IN)
- CRUK Lung Cancer Centre of Excellence (GB)
Publication Details
- Journal
- Scientific Reports
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1038/s41598-025-08388-2
- Citations
- 3
- Primary Topic
- vaccines and immunoinformatics approaches
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Department of Biotechnology, Ministry of Science and Technology, India
- Department of Science and Technology, Ministry of Science and Technology, India
- Council of Scientific and Industrial Research, India
- University Grants Commission
- Indian Institute of Technology Delhi